167 related articles for article (PubMed ID: 12127315)
1. Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution.
Dichtelmüller H; Rudnick D; Kloft M
Biologicals; 2002 Jun; 30(2):135-42. PubMed ID: 12127315
[TBL] [Abstract][Full Text] [Related]
2. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
3. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
4. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.
Burnouf T; Terpstra F; Habib G; Seddik S
Biologicals; 2007 Oct; 35(4):329-34. PubMed ID: 17363271
[TBL] [Abstract][Full Text] [Related]
5. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
[TBL] [Abstract][Full Text] [Related]
7. Iodine-mediated inactivation of lipid- and nonlipid-enveloped viruses in human antithrombin III concentrate.
Highsmith F; Xue H; Chen X; Benade L; Owens J; Shanbrom E; Drohan W
Blood; 1995 Jul; 86(2):791-6. PubMed ID: 7606009
[TBL] [Abstract][Full Text] [Related]
8. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation.
Omar A; Kempf C; Immelmann A; Rentsch M; Morgenthaler JJ
Transfusion; 1996 Oct; 36(10):866-72. PubMed ID: 8863772
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of lipid-enveloped viruses in proteins by caprylate.
Lundblad JL; Seng RL
Vox Sang; 1991; 60(2):75-81. PubMed ID: 2031341
[TBL] [Abstract][Full Text] [Related]
10. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
11. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
12. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
[TBL] [Abstract][Full Text] [Related]
13. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.
Torgeman A; Mador N; Dorozko M; Lifshitz A; Eschar N; White MD; Wolf DG; Epstein E
Biologicals; 2017 Jul; 48():24-27. PubMed ID: 28633975
[TBL] [Abstract][Full Text] [Related]
15. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
16. [Viral validation of the bio-globulin production process].
Zahorska R; Buchowicz I
Med Dosw Mikrobiol; 1995; 47(1-2):89-94. PubMed ID: 8523973
[TBL] [Abstract][Full Text] [Related]
17. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
18. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
19. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.
Ben-Hur E; Chan WS; Yim Z; Zuk MM; Dayal V; Roth N; Heldman E; Lazo A; Valeri CR; Horowitz B
Dev Biol (Basel); 2000; 102():149-55. PubMed ID: 10794102
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids.
Horowitz B; Piët MP; Prince AM; Edwards CA; Lippin A; Walakovits LA
Vox Sang; 1988; 54(1):14-20. PubMed ID: 2831669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]